|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Equity securities, at fair value (cost: $0 and $1,532) | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Restricted cash and cash equivalents | ||||||||||||||||||||
| Cat Re Token Program | ||||||||||||||||||||
| HCI 2026 Token Program | ||||||||||||||||||||
| Total restricted cash and cash equivalents | ||||||||||||||||||||
| Accrued interest and dividend receivable | ||||||||||||||||||||
| Restricted cash and cash equivalents | ||||||||||||||||||||
| Cat Re Token Program | ||||||||||||||||||||
| HCI 2026 Token Program | ||||||||||||||||||||
| Premiums receivable | ||||||||||||||||||||
| Other investments | ||||||||||||||||||||
| Loan receivable | ||||||||||||||||||||
| Due from related parties | ||||||||||||||||||||
| Total due from related parties | ||||||||||||||||||||
| Deferred policy acquisition costs | ||||||||||||||||||||
| Operating lease right-of-use assets | ||||||||||||||||||||
| Prepayment and other assets | ||||||||||||||||||||
| Prepaid Offering Costs | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities and Shareholders’ Equity | ||||||||||||||||||||
| Liabilities: | ||||||||||||||||||||
| Other liabilities: EpsilonCat Re / DeltaCat Re Tokenholders | ||||||||||||||||||||
| Reserve for losses and loss adjustment expenses | ||||||||||||||||||||
| Notes payable to noteholders | ||||||||||||||||||||
| Premium payable | ||||||||||||||||||||
| Unearned premiums reserve | ||||||||||||||||||||
| Other Liabilities - Delta Cat Re Token Holders | ||||||||||||||||||||
| Losses payable | ||||||||||||||||||||
| Loan payable | ||||||||||||||||||||
| Operating lease liabilities | ||||||||||||||||||||
| Accounts payable and other liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Mezzanine equity | ||||||||||||||||||||
| Cat Re / T20 / T42 tokenholders | ||||||||||||||||||||
| HCI 2026 Series A Tokens | ||||||||||||||||||||
| HCI 2026 Series B Tokens | ||||||||||||||||||||
| HCI 2026 Series C Tokens | ||||||||||||||||||||
| Total Mezzanine equity | ||||||||||||||||||||
| Shareholders’ equity: | ||||||||||||||||||||
| Ordinary share capital, (par value $0.001, 500,000,000 shares authorized; 8,101,374 and 7,664,122 shares issued and outstanding) | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated Deficit | ||||||||||||||||||||
| Total Oxbridge shareholders’ equity | ||||||||||||||||||||
| Non-controlling interests | ||||||||||||||||||||
| Total shareholders’ equity | ||||||||||||||||||||
| Total liabilities, mezzanine and shareholders’ equity | ||||||||||||||||||||
Loading...
